Zenas BioPharma Announces the Presentation of New Obexelimab Data in IgG4-Related Disease at the 6th International Symposium on IgG4-Related Disease

Zenas BioPharma presented new clinical data for obexelimab at the 6th International Symposium on IgG4-Related Disease. Phase 3 INDIGO open-label extension results showed sustained clinical activity with a 93% probability of remaining flare-free at 12 months, significantly reduced glucocorticoid toxicity compared to placebo, and positive vaccine responses during a treatment-free window. The data supports obexelimab's potential as a steroid-sparing B-cell inhibitor for long-term IgG4-RD management.